Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $26.09 USD
Change Today -0.28 / -1.06%
Volume 225.7K
QURE On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

uniqure b.v. (QURE) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/6/15 - $35.50
52 Week Low
05/22/14 - $8.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UNIQURE B.V. (QURE)

uniqure b.v. (QURE) Related Businessweek News

No Related Businessweek News Found

uniqure b.v. (QURE) Details

uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

162 Employees
Last Reported Date: 04/7/15
Founded in 1998

uniqure b.v. (QURE) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €484.0K
Compensation as of Fiscal Year 2014.

uniqure b.v. (QURE) Key Developments

Bristol-Myers Squibb Company and uniQure Collaborate to Develop New Cardiovascular Disease Therapies

Bristol-Myers Squibb Company and uniQure N.V. have signed a new agreement, under which BMS receives access for uniQure's gene therapy technology platform to develop new therapies for cardiovascular diseases. The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1. uniQure will lead discovery efforts and be responsible for manufacturing of clinical and commercial supplies using its vector technologies and its industrial, proprietary insect-cell based manufacturing platform. Bristol-Myers Squibb will lead development and regulatory activities across all programs and be responsible for all R&D costs. Bristol-Myers Squibb will be solely responsible for commercialization of all products from the collaboration. This collaboration will accelerate the application of gene therapy for large patient populations suffering from heart diseases and will complement the further development of uniQure's internal pipeline in two focus areas: liver diseases, including hemophilia, and CNS, including lysosomal storage diseases.

Bristol-Myers Squibb Company, uniQure N.V. - Special Call

To discuss the collaboration with Bristol-Myers Squibb Company i.e. Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases

uniQure N.V. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

uniQure N.V. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the period, the company reported licensing and collaboration revenues of €4.7 million, compared with €2.9 million in revenues in 2013.  Net loss was €37.0 million or €2.16 per share, compared to €26.8 million or €2.48 per share for the full year 2013. Operating result was negative at €33,834,000 compared to €22,535,000 a year ago. Negative result before corporate income tax was at €37,040,000 compared to €26,820,000 a year ago. Net cash used in operating activities was €25,425,000 compared to €4,136,000 a year ago. Purchases of property, plant and equipment was €15,769,000 compared to €1,336,000 a year ago. Purchases of intangible assets were €3,367,000 compared to €4,652,000 a year ago. For the three months ended December 31, 2014 the company recorded licensing and collaboration revenue of €1.5 million compared with €0.9 million for the same period in 2013. Net loss was €11.2 million, compared to €6.8 million for the comparable period in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QURE:US $26.09 USD -0.28

QURE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QURE.
View Industry Companies

Industry Analysis


Industry Average

Valuation QURE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 82.5x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 83.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNIQURE B.V., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at